| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/26/2009 | US20090081155 Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities |
| 03/26/2009 | US20090081139 Water-based delivery systems |
| 03/26/2009 | US20090081137 Crosslinked Polytetrahydrofuran-Containing Polyurethanes |
| 03/26/2009 | US20090081133 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations |
| 03/26/2009 | US20090081131 Tumor therapy with high affinity laminin receptor-targeted vectors and compounds |
| 03/26/2009 | US20090081125 Angiogenetic Agent Containing Adrenomedulin as the Active Ingredient |
| 03/26/2009 | US20090081124 Virus coat protein/receptor chimeras and methods of use |
| 03/26/2009 | US20090081123 Pharmaceutical compounds |
| 03/26/2009 | US20090081120 Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| 03/26/2009 | US20090081119 Inhibiting dna polymerase beta to enhance efficacy of anticancer agents |
| 03/26/2009 | DE102006050558B4 Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution Transdermal therapeutic system containing norelgestromin contraceptive and hormone replacement |
| 03/26/2009 | CA2849420A1 Anti-infective pyrimidines and uses thereof |
| 03/26/2009 | CA2737131A1 Therapeutic regimens for the treatment of immunoinflammatory disorders |
| 03/26/2009 | CA2711818A1 Method of reducing the effects of cytostatic drugs on bone marrow derived cells, and methods of screening |
| 03/26/2009 | CA2705719A1 Thieno-and furo-pyrimidine modulators of the histamine h4 receptor |
| 03/26/2009 | CA2704728A1 Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors |
| 03/26/2009 | CA2703019A1 Method and compositions for treatment or prevention of inflammatory conditions |
| 03/26/2009 | CA2700443A1 Certain substituted amides, method of making, and method of use thereof |
| 03/26/2009 | CA2700332A1 N-substituted piperidine derivatives as serotonin receptor agents |
| 03/26/2009 | CA2700331A1 Co-administration of pimavanserin with other agents |
| 03/26/2009 | CA2700327A1 Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof |
| 03/26/2009 | CA2700306A1 Chiral synthesis of diazepinoquinolines |
| 03/26/2009 | CA2700263A1 Soluble dosage forms containing cephem derivatives suitable for parenteral administration |
| 03/26/2009 | CA2700160A1 Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
| 03/26/2009 | CA2700072A1 Steroid containing ophthalmic drug delivery systems |
| 03/26/2009 | CA2700058A1 Novel tetrahydrofusedpyridines |
| 03/26/2009 | CA2700051A1 Small molecule bradykinin b1 receptor antagonists |
| 03/26/2009 | CA2699998A1 Compositions comprising stat5 sirna and methods of use thereof |
| 03/26/2009 | CA2699995A1 Compositions comprising stat3 sirna and methods of use thereof |
| 03/26/2009 | CA2699989A1 N-phenyl-dioxo-hydro pyrimidines useful as hepatitis c virus (hcv) inhibitor |
| 03/26/2009 | CA2699986A1 Anti-infective pyrimidines and uses thereof |
| 03/26/2009 | CA2699981A1 Uracil or thymine derivative for treating hepatitis c |
| 03/26/2009 | CA2699960A1 Use of r(+)-n-propargyl-1-aminoindan to treat or prevent hearing loss |
| 03/26/2009 | CA2699909A1 Process for preparing 1,3-dioxolan-2-ones as well as carboxylic acid esters by transacylation under basic reaction conditions |
| 03/26/2009 | CA2699892A1 Pyridyl sulfonamides as modulators of ion channels |
| 03/26/2009 | CA2699864A1 Method of treating gaucher disease |
| 03/26/2009 | CA2699859A1 Compositions and methods for the identification of inhibitors of retroviral infection |
| 03/26/2009 | CA2699854A1 Use of compounds comprising phosphorous for the treatment of cachexia |
| 03/26/2009 | CA2699849A1 Inhibitors of the interaction between mdm2 and p53 |
| 03/26/2009 | CA2699817A1 Benzimidazole nf- kappab inhibitors |
| 03/26/2009 | CA2699806A1 Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine |
| 03/26/2009 | CA2699761A1 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
| 03/26/2009 | CA2699707A1 Inhibitors of the interaction between mdm2 and p53 |
| 03/26/2009 | CA2699689A1 Substituted nicotinamide compounds and their use in medicaments |
| 03/26/2009 | CA2699638A1 Down-regulation of the gene expression by means of nucleic acid-loaded virus-like particles |
| 03/26/2009 | CA2699561A1 Methods of increasing sarcosine levels |
| 03/26/2009 | CA2699483A1 Compositions and methods for modulating immune function |
| 03/26/2009 | CA2699417A1 S1p receptor modulating compounds and use thereof |
| 03/26/2009 | CA2699338A1 Prodrugs to thyroid hormone analogs |
| 03/26/2009 | CA2699292A1 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 03/26/2009 | CA2699289A1 Thiazolidinedione analogues for the treatment of hypertension |
| 03/26/2009 | CA2699275A1 4-sulfonylpiperidine derivative |
| 03/26/2009 | CA2698814A1 Treatment of oestrogen dependant conditions in pre-menopausal women |
| 03/26/2009 | CA2698436A1 Tricyclic heterocyclic derivatives |
| 03/26/2009 | CA2697551A1 Piperidine derivatives as modulators of gpr119 activity |
| 03/26/2009 | CA2696914A1 Lyophilized pharmaceutical compositions |
| 03/26/2009 | CA2696776A1 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
| 03/26/2009 | CA2696508A1 Diacylglycerol acyltransferase inhibitors |
| 03/26/2009 | CA2696298A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 03/26/2009 | CA2695504A1 Compositions and methods for treatment and prevention of osteoarthritis |
| 03/26/2009 | CA2695435A1 Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease |
| 03/26/2009 | CA2693807A1 Foodstuff composition to improve digestibility of foodstuff lipids |
| 03/26/2009 | CA2693116A1 6-cycloamino-s-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof |
| 03/26/2009 | CA2692004A1 Methods and compositions to inhibit edema factor and adenylyl cyclase |
| 03/26/2009 | CA2691474A1 Cyanoisoquinoline |
| 03/26/2009 | CA2687689A1 Triazole-based aminoglycoside-peptide conjugates and methods of use |
| 03/25/2009 | EP2039779A1 Screening method |
| 03/25/2009 | EP2039767A1 PNA conjugates targeted to the EMU enhancer of the IGH locus as therapeutic agent for BCL-2 translocation-driven follicular cell lymphoma clonal expansion |
| 03/25/2009 | EP2039702A2 Prodrugs erbeta-selective substances, method for their production and pharmaceutical compounds containing these compositions |
| 03/25/2009 | EP2039701A2 20-keto-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 03/25/2009 | EP2039700A2 Novel anti-inflammatory androstane derivatives |
| 03/25/2009 | EP2039695A1 Bicyclic heterocyclic compound and use thereof |
| 03/25/2009 | EP2039694A1 CGRP receptor antagonists |
| 03/25/2009 | EP2039691A1 Process for production of a polymorph of 2-(3-cyano-4- isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid |
| 03/25/2009 | EP2039688A1 Fluorescent pyrazine derivatives and methods of using the same in assessing renal function |
| 03/25/2009 | EP2039687A1 Therapeutic or prophylactic agent for multiple sclerosis |
| 03/25/2009 | EP2039686A1 Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases |
| 03/25/2009 | EP2039685A2 Heterobicyclic compounds as P38 inhibitors |
| 03/25/2009 | EP2039683A2 Vasculostatic agents and methods of use thereof |
| 03/25/2009 | EP2039682A1 Salts for adding angiotensin conversion enzyme inhibitors to NO-donor acids, method of preparing same and pharmaceutical compositions containing them |
| 03/25/2009 | EP2039681A1 Cycloalkene derivatives, process for production of the derivatives, and use of the same |
| 03/25/2009 | EP2039369A1 Treatment of fungal infections |
| 03/25/2009 | EP2039367A1 Prophylactic/therapeutic agent for neurodegenerative disease |
| 03/25/2009 | EP2039363A1 Agent for prevention and/or treatment of glomerulopathy |
| 03/25/2009 | EP2039362A1 Tooth enamel dissolution inhibitor |
| 03/25/2009 | EP2039361A2 Use of immunomodulatory compounds |
| 03/25/2009 | EP2039360A1 Non-invasive direct delivery of opioids to the central nervous system |
| 03/25/2009 | EP2039359A1 Analgesic agent |
| 03/25/2009 | EP2039358A1 Pharmaceutical compositions comprising a macrolide and an acid |
| 03/25/2009 | EP2039357A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 03/25/2009 | EP2039356A1 Sialagogue composition comprising a M3 muscarinic agonist and an alpha-2 adrenergic antagonist |
| 03/25/2009 | EP2039355A2 Topical use of valproic acid for the prevention or treatment of skin disorders |
| 03/25/2009 | EP2039354A1 Compound having activity of blocking nmda receptor channel, and pharmaceutical agent using the same |
| 03/25/2009 | EP2039353A1 Reduced coenzyme q10-containing composition and method for producing the same |
| 03/25/2009 | EP2039350A1 Method of separating vesicle, process for producing medicinal preparation, and method of evaluation |
| 03/25/2009 | EP2039349A1 Solid pharmaceutical composition comprising donepezil hydrochloride |
| 03/25/2009 | EP2038659A2 Method for identifying crmp modulators |
| 03/25/2009 | EP2038415A1 Dph2 gene deletion mutant and uses thereof |
| 03/25/2009 | EP2038414A2 Cancer therapy using bcl-xl-specific sina |
| 03/25/2009 | EP2038294A1 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one) and pharmaceutical preparations containing the same |